TY - JOUR
T1 - A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases
T2 - A Danish multidisciplinary collaboration on prognostic factors and personalised medicine
AU - Andersen, Vibeke
AU - Holmskov, Uffe
AU - Sørensen, Signe Bek
AU - Jawhara, Mohamad
AU - Andersen, Karina W.
AU - Bygum, Anette
AU - Hvid, Lone
AU - Grauslund, Jakob
AU - Wied, Jimmi
AU - Glerup, Henning
AU - Fredberg, Ulrich
AU - Villadsen, Jan Alexander
AU - Kjær, Søren Geill
AU - Fallingborg, Jan
AU - Moghadd, Seyed A. G. R.
AU - Knudsen, Torben
AU - Brodersen, Jacob
AU - Frøjk, Jesper
AU - Dahlerup, Jens F.
AU - Nielsen, Ole Haagen
AU - Christensen, Robin
AU - Bojesen, Anders Bo
AU - Sorensen, Grith Lykke
AU - Thiel, Steffen
AU - Færgeman, Nils J.
AU - Brandslund, Ivan
AU - Stensballe, Allan
AU - Schmidt, Erik Berg
AU - Franke, Andre
AU - Ellinghaus, David
AU - Rosenstiel, Philip
AU - Raes, Jeroen
AU - Heitmann, Berit Lilienthal
AU - Boye, Mette
AU - Nielsen, Charlotte Lindgaard
AU - Werner, Lars
AU - Kjeldsen, Jens
AU - Ellingsen, Torkell
PY - 2017/5/15
Y1 - 2017/5/15
N2 - Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.
AB - Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.
KW - Journal Article
U2 - 10.3390/nu9050499
DO - 10.3390/nu9050499
M3 - Journal article
C2 - 28505128
SN - 2072-6643
VL - 9
JO - Nutrients
JF - Nutrients
IS - 5
M1 - 499
ER -